Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 83,820 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Not applicable Interventional Results available

iCBT With TMS in Patients With MDD

NCT05988619
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial Magnetic Stimulation, Internet-Based Cognitive Behavioral Therapy, Psychoeducation
Device · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 21, 2026, 7:34 AM EDT
Terminated Not applicable Interventional Results available

CBT-I for Cannabis Use

NCT02102230
View directory record Official record
Conditions
Marijuana Abuse, Sleep Initiation and Maintenance Disorders
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-I), Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA), Desensitization Treatment for Insomnia
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 21, 2026, 7:34 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Tolcapone in Obsessive Compulsive Disorder

NCT03348930
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Tolcapone 200 MG
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 21, 2026, 7:34 AM EDT
Active, not recruiting Phase 1 Interventional

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

NCT02659930
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
liposomal doxorubicin, pomalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 7:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy

NCT05905328
View directory record Official record
Conditions
Cytokine Release Syndrome
Interventions
CTO1681 10 µg, CTO1681 20 μg, CTO1681 30 μg, CTO1681 10 µg Run-in / 20 µg Treatment, CTO1681 20 µg Run-in / 30 µg Treatment
Drug
Lead sponsor
CytoAgents, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Orange, California • Augusta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 21, 2026, 7:34 AM EDT
Completed No phase listed Observational

KIDScore D3 Clinical Study

NCT03740828
View directory record Official record
Conditions
Infertility
Interventions
KIDScore D3
Device
Lead sponsor
Vitrolife
Industry
Eligibility
Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 21, 2026, 7:34 AM EDT
Recruiting Early Phase 1 Interventional

Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis

NCT03439865
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Ivacaftor, standard of care treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 7:34 AM EDT
Terminated Phase 1 Interventional

Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

NCT00290719
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, gefitinib, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 21, 2026, 7:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

NCT00983619
View directory record Official record
Conditions
B-cell Malignancies, Cancer
Interventions
MEDI-551, Rituximab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 21, 2026, 7:34 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach

NCT02614365
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Aerobic exercise, Stretch exercise
Behavioral
Lead sponsor
Howard University
Other
Eligibility
55 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 21, 2026, 7:34 AM EDT
Completed Phase 2 Interventional

Irofulven in Treating Patients With Metastatic Breast Cancer

NCT00003796
View directory record Official record
Conditions
Breast Cancer
Interventions
irofulven
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 21, 2026, 7:34 AM EDT
Terminated Phase 3 Interventional

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

NCT00060996
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
Interventions
Remodulin® (treprostinil sodium) Injection
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Tampa, Florida • Worcester, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 21, 2026, 7:34 AM EDT
Completed Not applicable Interventional

Helping Hypertensive Latinos to Improve Medication Adherence

NCT03560596
View directory record Official record
Conditions
Hypertension
Interventions
Adherence Intervention, Usual Care
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 21, 2026, 7:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Radiesse® Safety Study For the Treatment of Hands

NCT02904096
View directory record Official record
Conditions
Volume Loss in the Dorsum of the Hand
Interventions
Radiesse injectable implant and 2% lidocaine HCL
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
22 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
9
States / cities
Sacramento, California • San Diego, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 21, 2026, 7:34 AM EDT
Terminated Phase 2 Interventional Results available

Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)

NCT01212588
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
mifepristone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 64 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 21, 2026, 7:34 AM EDT
Recruiting Not applicable Interventional

Sacramento Clinical High Risk for Psychosis Stepped-Care Program

NCT06640803
View directory record Official record
Conditions
Clinical High Risk for Psychosis, Ultra High Risk for Psychosis
Interventions
Stepped-Care including Cognitive Behavioral Case Management
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 25 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Elk Grove, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 21, 2026, 7:34 AM EDT
Withdrawn Phase 2 Interventional

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

NCT03365661
View directory record Official record
Conditions
High-Risk Acute Myeloid Leukemia, Treatment-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
ALT-803
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 21, 2026, 7:34 AM EDT
Withdrawn Phase 2 Interventional

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

NCT02763761
View directory record Official record
Conditions
Renal Cell Carcinoma, Melanoma, Lung Cancer
Interventions
Infliximab + Prednisone, Methylprednisolone + Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 21, 2026, 7:34 AM EDT
Completed No phase listed Observational

Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

NCT00280761
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, 5-fluorouracil, Surgical Resection, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 21, 2026, 7:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 21, 2026, 7:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

NCT00045942
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Itraconazole, PKC412
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 21, 2026, 7:34 AM EDT
Active, not recruiting Not applicable Interventional

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

NCT01918683
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Maywood, Illinois • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 21, 2026, 7:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 21, 2026, 7:34 AM EDT
Completed Phase 3 Interventional Results available

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

NCT00003641
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
interferon alfa-2b, observation
Biological · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2026
U.S. locations
511
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 354 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 7:34 AM EDT